Thus, amyloid imaging plays a critical role in this regard and any future trials of putative tau-based disease modifying therapies that enroll patients with CBS and PSP would need to exclude AD using these methods. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.